Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-07022025-260823
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 657]
NEW DELHI, FRIDAY, FEBRUARY 7, 2025/MAGHA 18, 1946
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 7th February, 2025
S.O. 661(E).—- In implementation of directions of review order issued by the Department of Pharmaceuticals
(DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the table below and
in exercise of the powers conferred by paragraphs 5,11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O.
1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in
the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry
of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. and date specified in the Column (7)
of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as
specified in column (5) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in
relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit
and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (8)
thereof;
TABLE
+-----+-----------------+-----------------------------------+-------+-------------+--------------------+--------------------+-----------------------------+
| S. | Name of the | Dosage form & | Unit | Retail | DoP Review | Existing SO | Manufacturer |
| No. | Formulation | Strength | | Price | no. & Date | number & | & Marketing |
| | | | | (Rs.) | | date | Company |
| | | | | | | | respectively |
+=====+=================+===================================+=======+=============+====================+====================+=============================+
| (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) |
+-----+-----------------+-----------------------------------+-------+-------------+--------------------+--------------------+-----------------------------+
| 1. | Cilnidipine | Each film coated | 1 | 14.15 | 31015/60/2023- | 1434(E) dated | M/s Akums |
| | & | tablet contains: | Tablet| | Pricing dated | 27.03.2023 | Drugs & |
| | Telmisartan | Cilnidipine IP 20mg | | | 04.10.2024 | (at Sl. No.22) | Pharmaceuticals |
| | Tablets | Telmisartan IP 40mg | | | | | Ltd. / M/s |
| | | | | | | | Glenmark |
| | | | | | | | Pharmaceuticals |
| | | | | | | | Limited |
+-----+-----------------+-----------------------------------+-------+-------------+--------------------+--------------------+-----------------------------+
Note:
(a) The manufacturer as specified in column (8), of the above mentioned formulations i.e. "new drug" under
paragraph 2(1)(u) of the DPCO, 2013 may revise the retail price as specified in column (5) of the table
hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (5) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification
as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for
generic / any brand of the same composition / strength of the subject formulations, subject to fulfilment of all
the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including
manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as
may be applicable, by the concerned manufacturers/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification
and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit
the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with
the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in
Column (3) & (8) thereof, the price order(s) fixing the retail price of the formulation with specified strength
for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (8)
thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/261/129/2025/F/F. No. 8(129)/2025/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director